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Background: In airways, a proliferative effect is played directly by cholinergic agonists through nicotinic and
muscarinic receptors activation. How tumors respond to aberrantly activated cholinergic signalling is a key question
in smoking-related cancer. This research was addressed to explore a possible link of cholinergic signalling changes
with cancer biology.
Methods: Fifty-seven paired pieces of head and neck squamous cell carcinoma (HNSCC) and adjacent non-cancerous
tissue (ANCT) were compared for their mRNA levels for ACh-related proteins and ACh-hydrolyzing activity.
Results: The measurement in ANCT of acetylcholinesterase (AChE) and butyrylcholinesterase (BChE) activities
(5.416 ± 0.501 mU/mg protein and 6.350 ± 0.599 mU/mg protein, respectively) demonstrated that upper
respiratory tract is capable of controlling the availability of ACh. In HNSCC, AChE and BChE activities dropped to
3.584 ± 0.599 mU/mg protein (p = 0.002) and 3.965 ± 0.423 mU/mg protein (p < 0.001). Moreover, tumours with
low AChE activity and high BChE activity were associated with shorter patient overall survival. ANCT and HNSCC
differed in mRNA levels for AChE-T, α3, α5, α9 and β2 for nAChR subunits. Tobacco exposure had a great impact
on the expression of both AChE-H and AChE-T mRNAs. Unaffected and cancerous pieces contained principal AChE
dimers and BChE tetramers. The lack of nerve-born PRiMA-linked AChE agreed with pathological findings on nerve
terminal remodelling and loss in HNSCC.
Conclusions: Our results suggest that the low AChE activity in HNSCC can be used to predict survival in patients
with head and neck cancer. So, the ChE activity level can be used as a reliable prognostic marker.
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Head and neck carcinomas arise in the mucosal layer of
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article, unless otherwise stated.each year, head and neck neoplasia is the sixth most fre-
quent cancer [1, 2]. Patients with HNSCC at early stage
can be cured with aggressive multimodal therapy (sur-
gery, radiation, and/or chemotherapy). Unfortunately, no
treatment is still available to reach fully satisfactory
achieves, and, therefore, the mortality rate of HNSCC
patients remains high [3]. Novel and reliable biomarkers
for distinguishing patients with poor prognosis or great
risk of early recurrence, and for using personalized ther-
apies are still awaited given to uncertainty in clinical
evolution of HNSCC using current staging criteria.d Central. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/4.0), which permits unrestricted use,
, provided the original work is properly credited. The Creative Commons Public
mons.org/publicdomain/zero/1.0/) applies to the data made available in this
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cell types are capable of expressing the range of proteins
that form a non-neuronal cholinergic system i.e. the ACh-
synthesizing enzyme choline acetyltransferase (ChAT),
nicotinic (nAChR) and muscarinic (mAChR) receptors,
and the ACh-hydrolyzing enzymes acetyl- (AChE) and bu-
tyrylcholinesterase (BChE) (reviewed in reference [4]). Its
great catalytic efficiency allows AChE working as an ideal
molecular machine for controlling and stopping ACh-
elicited actions [5]. On the other hand, most tissues and
body fluids contain a second ChE named BChE. Despite
the lower catalytic efficiency of BChE than AChE at the
time to hydrolyze acetylcholine, BChE contributes to ACh
homeostasis as judged by its role in AChE-null mice [6, 7].
The catalytic action of AChE and BChE ensures rapid
withdrawal of ACh, which, otherwise, may lead to cholin-
ergic over-activation.
In the context of a cell type-specific cholinergic pheno-
type, it is worth noting the results that demonstrate that
the human respiratory tract epithelium possesses a non-
neuronal cholinergic system engaged in controlling the
level of ACh. It seems that this epithelial cholinergic sys-
tem operates actively to regulate auto/paracrine actions
and by this means controls reliably basic cell functions
[8]. The cell proliferation effects arising from choliner-
gic over-activation, via endogenous ACh or nicotine-
derived carcinogens, gain significance when considering
the susceptibility to lung cancer that confers AChR disor-
ders [9], the nicotine-guided shift in the expression pattern
of AChR to proliferating/migrating cell phenotypes [10],
and the promising therapies based in the blockade or at-
tenuation of cholinergic signalling [11–13].
The information relative to AChE and BChE involve-
ment in cell proliferation and differentiation [14] makes
it possible that ChEs take part in tumour development.
In support of this idea are: 1) the frequent aberrations
in the AChE gene and the structural changes in AChE
proteins observed in tumours of diverse origin [8, 15–19];
2) the expression of AChE during and after apoptosis in-
duction with different stimuli [20–22]; and 3) the profit-
able use as a prognostic predictor for liver carcinoma of
AChE and its profitable effects through suppression of cell
growth and enhancement of chemosensitization [23].
The contribution of cholinergic signalling to cancer
onset and growth [24] and our previous reports showing
that neoplastic transformation alters the level of AChE
and/or BChE activities and the content of ChE-mRNAs
in human breast, lymph node, intestine, lung, kidney
and prostate [8, 18, 25, 26] prompted us to compare un-
affected tissue samples and head and neck tumours for
possible changes in the expression of AChE and BChE,
which would alter the availability of ACh, and to test the
usefulness of the changes in ChE expression as reliable
diagnostic or prognostic markers.Methods
Patients and samples
A total of 57 human malignant primary carcinomas
(HNSCC) and their adjacent noncancerous tissues
(ANCT) taken in the surgery act made at Virgen de la
Arrixaca Clinical University Hospital in Murcia (Spain)
from 2007 to 2011 were included in the current study.
Fresh specimens were divided into sections and stored at −
80 °C until use. The TNM classification of HNSCC speci-
mens was made according to the UICC:TNM Classification
of Malignant Tumours. The study approval and the con-
sent procedure were obtained from the Institutional Ethic
Committee of our Hospital. All patients gave their consent
after being appropriately informed.
Extraction and assay of cholinesterases
Cholinesterases were extracted from surgical ANCT and
HNSCC pieces by homogenization (5 % w/v) with Tris-
saline buffer (TSB; 1 M NaCl, 50 mM MgCl2, 3 mM
EDTA, 10 mM Tris, pH 7.0) supplemented with 1 % Brij
96 and a fresh mixture of proteinase inhibitors (0.1 mg/ml
soybean trypsin inhibitor, 1 mg/ml bacitracine, 0.0022
TIU/ml aprotinin, 10 mg/ml pepstatin A and 20 mg/ml
leupeptin). After centrifugation at 30,000 rpm, 1 h at 4 °C,
in a 70Ti Beckman rotor (Palo Alto, CA, USA), the super-
natant with AChE and BChE was saved. For assays with
fluorochrome-tagged physostigmine (Ph-F) proteinase in-
hibitors were not added to the extraction buffer.
Cholinesterase activity was determined as earlier [8]
and protein concentration by BioRad Protein Assay with
bovine serum albumin as the standard.
Sedimentation analysis
Possible differences between ANCT and HNSCC in the
molecular distribution of AChE and BChE were tested
by sedimentation analysis in sucrose gradients as re-
ported before [8]. Briefly, samples and sedimentation
markers (bovine liver catalase and intestine alkaline
phosphatase) were layered on the top of centrifuge tubes
containing 5 - 20 % sucrose gradients, in the presence of
0.5 % w/v Brij 96 detergent. The gradient tubes were cen-
trifuged at 35,000 rpm in a SW41Ti rotor in a Beckman
L–80 OPTIMA XP Ultracentrifuge (Fullerton, CA, USA),
18 h at 4 °C. After centrifugation, fractions of 250 μl were
collected from the tube bottom and assayed for AChE and
BChE activities and enzyme markers.
mRNA Isolation and real-time PCR
Differences between ANCT and HNSCC specimens in
the expression level of cholinergic components were stud-
ied by RT-PCR. For this, mRNA was extracted from tis-
sues using the Chemagic mRNA Direct Kit (Chemagen),
and reversed transcribed into cDNA by random priming
(GeneAmp RNA-PCR kit, Applied Biosystems). A
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Mannheim, Germany) was used for RT-PCR. Pairs of
primers were designed for quantitative PCR targeting of
the 3’-alternative AChE mRNAs (R, H, or T) and the tran-
scripts for BChE, choline acetyltransferase (ChAT),
proline-rich membrane anchor (PRIMA), nAChR subunit
genes α3, α5, α7, α9, β2, and β4; and mAChR subunit
genes M2 and M3. The transcripts for β-actin and
GAPDH were used for internal normalization. Reaction
conditions were validated separately for each pair of
primers, with single peak of dissociation curves produced
in each run of reaction. The sequence and position of the
primers, as well as the size of the PCR products, are pro-
vided in Additional file 1: Material. The buffered medium
contained 5 μL of variable dilutions of cDNA, 0.3 μM spe-
cific primers, and a volume of PCR master mix to complete
20 μL. Reactions comprised a first step of 30 sec min at
95 °C, followed by 40 cycles of 10 seconds to 95 °C, 10 sec-
onds at 60 °C, 15 seconds at 72 °C. A final dissociation
stage allowed us to study the melting curves. The relative
content of cDNAs, with respect to β-actin cDNA, was de-
termined by the second derivative method with kinetic
PCR efficiency correction. PCR products were separated in
2 % agarose gels and visualized with GelRed Nucleic Acid
Gel Stain (Biotium) to check that their lengths coincided
with the expected size. Negative controls (without reverse
transcriptase) for each primer pair were also made.
Western blotting
AChE subunits of ANCT and HNSCC were resolved by
reducing SDS-PAGE [27] in 12.5 % polyacrilamide-gel
slabs. Proteins were electro-transferred to PVDF mem-
branes, blocked with 5 % non-fat dried milk and incu-
bated with the N19 anti-AChE antisera (Santa Cruz).
Since N19 antibodies are produced against the N-
terminal peptide of human AChE, they should react
with the full set of AChE variants. Labelled proteins
were revealed using suitable horseradish peroxidase-
conjugated antibodies and the Pierce ECL2 Western
blotting substrate (Thermo Scientific). The size of AChE
subunits was estimated using appropriate protein stan-
dards Full Range Rainbow Molecular Weight Markers
(GE Healthcare), and the intensity of the protein bands
was quantified using GelPro Analyzer Software (version
3.1; Media Cybernetic). β-actin was used as a loading
control.
In addition, the use of fluorescein-tagged physostigmine
(Ph-F) allowed us a direct observation of the resolved
AChE subunits. For this, protein extracts from non-
cancerous and cancerous pieces were adjusted to 1 mg/ml
in Tris buffer, and treated with 2 μM Ph-F, 30 min at room
temperature. Afterwards, the reaction was quenched by
adding its volume of reducing electrophoresis sample buf-
fer. Proteins were separated by SDS/PAGE in 4–12 %polyacrylamide slabs, and visualized in-gel with a GE
Healthcare Typhoon™ fluorescence scanner.
Statistical analysis
The results are given as a mean ± SEM. Numeric data
were analyzed for statistical significance using Mann-
Whitney test. Statistical significance for mean values was
set-up at p < 0.05. Kaplan-Meier curves were constructed
to assess disease-free (DFS) or overall (OS) survival. The
starting point for survival studies was the date of surgi-
cal act and the final point was the manifestation of ei-
ther local recurrence or distant metastatic dissemination
(DFS), or death (OS). Differences between groups were
analysed using the log-rank test for equality of survivor.
A difference of p < 0.05 was considered to be statistically
significant. Data were analyzed using the SPSS software,
version 15.0 (SPSS Inc., Chicago, IL).
Results
Characteristics of patients
Fifty-seven patients participated in this research (Table 1).
They were grouped according to sex, age, tobacco expos-
ure, alcohol consumption, anatomical tumour location,
differentiation grade (well versus poor and moderately dif-
ferentiated), clinical stage (I and II versus III and IV), and
lymph node affectation (N0 versus N+).
The age of patients ranged 24–89 years, with mean ±
SD of 66.55 ± 11.42. Most patients were male (93.3 %) as
well as current or former smokers (79.8 %). The preva-
lent tumour location was the larynx (49/57; 85.95 %),
with carcinomas distributed between the glottis (28/57;
49.12 %) and supraglottis areas (21/57; 36.84 %). A few
HNSCC were located in the hypopharynx (2/57; 3.51 %),
oral cavity (4/57; 7.02 %) and paranasal sinus (1/57; 1.75
%) (Table 1). Among the tumours tested, 36/57 (63.16
%) were at late stage (III and IV) and 19/57 (33.33 %) at
early stage (I and II). The percentages of well, moder-
ately, and poorly differentiated tumours were 31.58 %
(18/57), 40.35 % (23/57), and 33.33 % (19/57), respect-
ively. The analysis of correlation of demographic and
pathological parameters with outcome of HNSCC pa-
tients is showed in Table 2.
Both AChE and BChE activities were decreased in head
and neck carcinomas
The observation in non-neural human tissues of cholinergic
components [28] prompted us to examine their expression
levels in human upper respiratory tract epithelium. So, tak-
ing into account the importance of ChEs for regulating
ACh levels, and therefore, for controlling the intensity and
duration of cholinergic signals, ChE activity levels in ANCT
and HNSCC pieces were compared. The observation in
ANCT of AChE and BChE activities (5.416 ± 0.501 mU/mg
protein and 6.350 ± 0.599 mU/mg protein) demonstrated
Table 1 Summary of demographic characteristics of HNCSS patients and acetyl- and butyrylcholinesterase activity in upper
respiratory epithelium
AChE activity (mU/mg protein) BChE activity (mU/mg protein)
Samples N ANCT Tumour P-value ANCT Tumour P-value
Total 57 5.416 ± 0.501 3.584 ± 0.633 0.002 6.350 ± 0.599 3.965 ± 0.423 <0.001
Gender
Male 53 5.094 ± 0.473 3.525 ± 0.674 0.003 6.278 ± 0.638 3.952 ± 0.450 0.001
Female 4 9.680 ± 2.962 4.363 ± 1.395 0.273 5.730 ± 1.303 3.142 ± 0.843 0.068
Age
<60 18 6.175 ± 0.929 4.553 ± 1.390 0.145 7.007 ± 1.311 4.572 ± 0.808 0.093
>60 39 5.066 ± 0.593 3.136 ± 0.669 0.005 5.891 ± 0.648 3.825 ± 0.495 0.002
Tobacco
Non-smoker 5 4.978 ± 1.556 3.135 ± 1.820 0.225 3.891 ± 0.876 3.657 ± 0.922 0.893
Smoker 46 5.145 ± 0.510 3.721 ± 0.741 0.017 6.852 ± 0.716 3.872 ± 0.431 <0.001
Alcohol
No 17 5.219 ± 0.621 3.524 ± 0.695 0.290 5.807 ± 1.034 4.701 ± 0.645 0.650
Yes 16 5.921 ± 0.822 3.737 ± 1.425 0.034 6.491 ± 0.745 3.746 ± 0.445 <0.001
Location
Glottic 29 4.736 ± 0.663 3.467 ± 0.902 0.003 5.978 ± 0.794 3.612 ± 0.697 0.004
Supraglottic 21 5.200 ± 0.607 4.423 ± 1.201 0.017 7.593 ± 1.205 4.299 ± 0.603 0.007
Other 7 8.374 ± 1.699 2.699 ± 0.692 0.052 4.544 ± 0.530 4.362 ± 0.843 1.000
Differentiation
Well 17 5.279 ± 0.828 4.057 ± 1.473 0.227 5.013 ± 0.806 3.771 ± 0.828 0.193
Moderate/Poor 32 5.123 ± 0.637 3.631 ± 0.807 0.030 7.684 ± 0.947 4.334 ± 0.622 0.002
Clinical Stage
Stage I + II 19 4.660 ± 0.717 2.638 ± 0.714 0.059 6.118 ± 0.849 4.046 ± 0.858 0.058
Stage III + IV 36 5.319 ± 0.598 4.167 ± 0.921 0.033 6.568 ± 0.829 3.951 ± 0.504 0.002
Nodal Status
N0 30 4.780 ± 0.530 3.231 ± 0.754 0.077 6.438 ± 0.857 3.624 ± 0.534 0.003
N+ 19 5.301 ± 0.943 3.432 ± 1.335 0.032 6.644 ± 1.006 4.878 ± 0.838 0.039
T Stage
T1 4 4.707 ± 1.638 1.405 ± 0.670 0.068 4.456 ± 0.583 2.228 ± 0.367 0.068
T2 16 4.485 ± 0.790 2.893 ± 0.822 0.179 7.293 ± 1.302 4.265 ± 0.952 0.063
T3 24 5.727 ± 1.178 4.600 ± 1.562 0.382 6.522 ± 1.681 3.815 ± 0.559 0.110
T4 11 5.224 ± 0.692 4.019 ± 1.214 0.031 6.085 ± 0.853 4.331 ± 0.756 0.028
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ity of ACh. In HNSCC, AChE and BChE activities
dropped to 3.584 ± 0.633 mU/mg (p = 0.002) and 3.965 ±
0.423 mU/mg (p < 0.001), respectively (Table 1).
A possible pathological significance for the changing
ChE activity was examined by comparing AChE and
BChE activities in tumours and their clinico-pathological
parameters. The results showed that AChE activity in
HNSCC was significantly lower relative to ANCT in the
smokers group (p = 0.017), alcohol drinking group (p =
0.034), moderate and poor differentiation grade (p = 0.030),clinical stage III + IV group (p = 0.033), and lymph node-
positive group (p = 0.032) (Table 1). No association between
AChE activity and HNSCC aggressiveness was observed.
Since it has been reported that serum AChE levels go up
with age [29], tissue ChE activities were tested in associ-
ation with age. No significant association between AChE
activity and age was found (Spearman's rank correlation
coefficient = 0.059, p = 0.663; Pearson's correlation coeffi-
cient = 0.053, P = 0.695).
As regards BChE activity, its level was also found signifi-
cantly decreased in cancerous pieces (Table 1). Lower
Table 2 Correlation of variables with outcome in head and
neck carcinomas
Variable Overall survival
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ANCT correlated with smoking (p < 0.001), alcohol con-
sumption (p < 0.001), poorer differentiation grade (p =
0.002) and advanced clinical stage (p = 0.002).
AChE and BChE activity was measured in serum from
cancer patients and in age-matched control group.
Serum in all HNSCC patients contained significant level
of both AChE and BChE activity. Values of both AChE
and BChE were in the normal range thus it can be ex-
cluded that differences in cholinesterase levels exist due to
genomic changes. Serum AChE activity was 0.63 ±
0.08 mU/ml and BChE activity was 140.47 ± 7.24 mU/ml.
However, the results indicated that both AChE and BChE
activities in serum of HNSCC patients were significantly
lower than in the control group (1.09 ± 0.07 mU/ml for
AChE and 176.43 ± 9.05 mU/ml for BChE; p < 0.001 and
p = 0.007, respectively). These results are in agreement
with published data demonstrating lower ChE levels in
serum from cancer patients [30–33].Survival and cholinesterase activity
In our attempts to test whether ChE activity might be
used as a prognostic marker, overall (OS) and disease-
free (DFS) survival rates of patients were measured. The
median follow-up time was 29.04 months (range 6–60
months), and a cut-off value of the 50th percentile of
AChE (1.801 mU/mg protein) and BChE (2.967 mU/mg
protein) was set-up when comparing activity values in
tumours with OS and DFS rates of the study population.
The results indicated that tumours with AChE activity
below 1.801 mU/mg were statistically associated with
poorer OS (p = 0.014; Fig. 1a), but not with shorter DFS
(p = 0.560; Fig. 1c). As for BChE activity, patients with
high tumour BChE activity (>2.967 mU/mg protein) had
a poorer prognosis relative to both OS (Fig. 1b; p =
0.024) and DFS (Fig. 1d; p = 0.038). When Survival was
evaluated by combining AChE and BChE activities, pa-
tients with AChE low/BChE high had shorter OS (p =
0.002) and DFS (p = 0.047) when compared with AChE
high/BChE low samples (Fig. 1e-f ).
Among the available pathological and clinical variables
(Table 1), advanced clinical stage (III + IV) and affected
lymph nodes (N+) were significantly associated with
shorter survival (Additional file 1: Figure S2 C-D). Sub-
sequently, prediction of shorter survival associated with
low AChE activity was tested in the multivariate analysis
by Cox proportional hazards regression model, adjusting
for clinical stage and for spreading to lymph nodes. Re-
sults showed that low AChE activity was an independent
prognostic marker respect to clinical stage (ExpB 2.48,
CI 1.130-5.444, p = 0.021) and lymph node status (ExpB
2.444, CI 1.073-5.570, p = 0.033). For BChE we found
also statistical significance when clinical stage (ExpB
3.517, CI 0.978-12.655, p = 0.044) or lymph node status
(ExpB 5.385, CI 1.190-24.365, p = 0.029) were tested.
As the differences in AChE activity were observed
comparing mean values in ANCT and HNSCC pieces,
OS rates were compared with the ratios of AChE activity
in HNSCC and its ANCT sample. Despite the early mor-
tality showed by patients with high difference in AChE
activity between ANCT and HNSCC pieces (ratio >
1.92), the results did not reach statistical significance
(Additional file 1: Figure S1A; p = 0.071). When the
ANCT to HNSCC BChE activity ratio was compared,
OS rates also failed in reaching statistical significance
(Additional file 1: Figure S1B; p = 0.099).
Gene expression of cholinergic components in head and
neck carcinoma
The lower ChE activity in HNSCC pieces may arise from
gene down-regulation, a possibility that was assessed by
measuring AChE and BChE mRNA levels in unaffected
and cancerous pieces. The data showed that ANCT sam-
ples contained principal AChE-T mRNA and less AChE-
Fig. 1 Kaplan-Meier estimated overall (OS) and disease-free survival (DFS) rates according to ChE activity values. Tumours (n = 57) were split into
those that exhibited higher or lower values than the 50th percentile for AChE activity (1.801 mU/mg protein; a, c), for BChE activity (2.967 mU/mg
tissue; b, d) or for the combination of AChE and BChE for OS (e) and DFS (f). Low tumour AChE activity was found to be statistically associated
with adverse OS rate (p = 0.014) (a), but not with shorter DFS rate (p = 0.560) (c). High BChE activity in tumours was associated with both adverse
OS (p = 0.020, b) and DFS (p = 0.030; d). The combination of AChE and BChE (“AChE high/BChE low” vs “AChE low/BChE high”) were statistically
linked with adverse OS (p = 0.002) (e) and DFS (p = 0.047) (f)
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level was significantly lower in HNSCC pieces (Fig. 2a)
meanwhile AChE-H and AChE-R mRNAs tended to
decrease with cancer but did not reach statistical signifi-
cance. Contrary to AChE, BChE was found to be up-
regulated in head and neck carcinoma as judged by the
negligible level of BChE mRNA in ANCT and its strong
increase in HNSCC (Fig. 2a).
Since smoking is strongly associated with head and
neck cancer, correlation between tobacco exposure and
level of expression of AChE and BChE mRNAs was
assessed (Fig. 2b). Both ANCT and HNSCC tissues from
smoker patients showed much lower level of AChE-H
and AChE-T mRNA respect to tissues from non-smoker,
indicating that tobacco components downregulate ex-
pression of ACh-hydrolyzing enzymes.Afterwards, considering that the expression of AChE and
BChE genes frequently changes with development and/or
proliferation states [34], the possibility remained that tu-
mours with distinct differentiation grading displayed un-
equal patterns of AChE or BChE mRNAs. PCR data
indicated that while well and moderately differentiated tu-
mours contained lower AChE mRNA (Additional file 1:
Figure S2A), the opposite applied for poorly differentiated
tumours (Additional file 1: Figure S2B). Meanwhile, BChE
expression was up-regulated regardless of the tumour
histological grade (Additional file 1: Figure S2A-B). A com-
parison of the changing levels of AChE and BChE mRNAs
in carcinomas according to their anatomical location also
showed differences (Additional file 1: Figure S2C-D).
In our attempts to assess if the expression of the pro-
teins required for establishing a putative ‘oncogenic’
Fig. 2 Histograms showing differences between unaffected and
cancerous pieces in the levels of the distinct AChE mRNA variants and
the single BChE transcript. mRNA of adjacent non cancerous tissues
(ANCT; blue bars) and of head and neck squamous cell carcinomas
(HNSCC; red bars). mRNA was extracted, retro-transcribed and amplified
using the primers indicated in Additional file 1: Table S1. β-actin and
GAPDH mRNAs were used as the housekeeping markers. AChE-T,
AChE-H, and AChE-R stand for tailed (synaptic) AChE, hydrophobic
(erythrocytic) AChE, and read-through AChE. AChE and BChE mRNA
levels in HNSCC and ANCT pieces (a) and in tissues from smoker and
non smoker patients (b). Note the lower AChE-T mRNA level (p = 0.036)
and higher BChE mRNA level (p = 0.015) in HNSCC than ANCT pieces
(a) and the significant decrease of both AChE-T and AChE-H mRNA
levels in ANCT (dark blue) and HNSCC (dark red) tissues from smoker
patients. (* p < 0.05)
Fig. 3 mRNA levels for proteins involved in cholinergic signalling in
ANCT (white bars) and HNSCC specimens (black bars). Note the
negligible level of ChAT mRNA in ANCT and HNSCC and the
absence from the tissue specimens of detectable PRiMA mRNA
(not showed). (* p < 0.05)
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levels for nAChR and mAChR, ChAT, and PRiMA were
also studied. The negligible level of ChAT mRNA in
ANCT and the absence of PRiMA mRNA from it, ruled
out an active synthesis of ChAT and PRiMA proteins in
upper respiratory tract epithelium. However, the observa-
tion in ANCT of α7 and α5 mRNAs, and fewer α3, α9, β2
and β4 mRNAs for nAChR subunits (Fig. 3) supported the
production in airway epithelium of heteromeric nAChR,
consisting of α3, α5, β2 and β4 subunits, and homomeric
nAChR made of α7 or α9 subunits. Moreover, the pres-
ence of mRNAs for M2 and M3 mAChR in unaffected
and cancerous tissues (Fig. 3) supported the translation
and membrane targeting of Gi-coupled and Gq-coupled
mAChR in airway epithelium. The differences between
ANCT and HNSCC in the relative content of the mRNAs
for α3, α5, α9, and β2 proteins (Fig. 3) supported cancer-
induced changes in the availability of proteins involved in
cholinergic signalling.Molecular distribution of AChE and BChE in upper tract
respiratory epithelium
The fact that the normal distribution of ChE compo-
nents was frequently altered in pathological tissues
prompted us to compare the pattern of AChE and BChE
molecules in upper tract respiratory epithelium. Sedi-
mentation analysis revealed abundant 4.4 ± 0.2S AChE
forms, and fewer 9.7 ± 0.2S and 3.0 ± 0.1S components
in ANCT and HNSCC pieces (Fig. 4). According to pre-
vious data [25], the major 4.4S forms were assigned to
amphiphilic AChE dimers (G2
A), most probably consist-
ing of GPI-linked AChE, arising from the AChE-H
mRNA. The 3.0S forms were attributed to GPI-bound
G1
A AChE, and the 9.7S forms to PRiMA-bound tetra-
mers (G4
A), consisting of four AChE-T subunits bonded
to PRiMA. The distribution of AChE forms was similar
in most ANCT pieces tested, except for G4
A AChE
which lacked in 4 out the 14 pieces analyzed. Of note
was the absence of PRiMA-bearing tetramers from
HNSCC of glottis and supraglottis locations (Fig. 4).
As regards BChE, sedimentation profiles showed
major hydrophilic tetramers (G4
H; 12.0 ± 0.2 S) and less
PRiMA-linked tetramers (G4
A; 9.9 ± 0.3 S) and hydro-
philic monomers (G1
H; 4.6 ± 0.2 S) in ANCT samples.
The presence in airway epithelium of G1
H BChE (Fig. 4),
which lacked from human plasma demonstrated the epi-
thelial cell origin of BChE. Moreover, the neural origin
of PRiMA [35] supported a nerve source of the PRiMA-
linked BChE tetramers identified in most cancerous
pieces of supraglottis location.
Detection of proteins by western-blotting and
activity-based protein profile
After reporting that cultured lung cancer cells and tis-
sues possess the capacity to express both catalytically
Fig. 4 Sedimentation profiles depicting AChE and BChE components in human upper respiratory epithelium. Molecular forms AChE and BChE in
unaffected (empty circles) and cancerous tissues (filled circles) in glottis (G) and supraglottis areas (S)
Fig. 5 Immunoblotting of AChE in human upper airway epithelium.
Proteins in non cancerous (Healthy; H) and cancerous (Tumour, T)
pieces were separated by reducing SDS-PAGE and detected by
western blotting with anti-AChE antibodies. The use of N19
antibodies allowed us to observe two-three deeply labelled protein
bands of about 60-kDa and various fainter bands of 70–76 kDa (a).
The active site-directed probe Ph-F was able to label the 70–76 kDa
bands, but not the 60-kDa proteins (b). Accordingly, the deep
60-kDa protein bands in ANCT and HNSCC specimens were assigned
to non-catalytic AChE proteins, and the faint 70–76 kDa bands to
catalytic proteins. Note the much weaker signal corresponding to
catalytic AChE in tumours (T) than healthy (H) tissues. The loaded
control was β-actin (c)
Castillo-González et al. BMC Cancer  (2015) 15:385 Page 8 of 13competent and non-competent AChE molecules [8] in-
sights into possible differences in size and abundance of
active and inactive AChE subunits were gained by
western-blotting of unaffected and cancerous tissue ex-
tracts using N19 antibodies. Deep 60-kDa and weak 70–
76 kDa protein bands were observed (Fig. 5a), and like
in lung epithelia [8], the lack of correlation between the
AChE units loaded in the gel lanes and the labelling in-
tensity demonstrated the presence of inactive AChE
molecules in ANCT.
Moreover, the usefulness of probes directed to the
catalytic site of enzymes (activity-based protein profile;
ABPP methodology) to label catalytically competent en-
zymes in complex proteomes [36] prompted us to take
advantage of the efficient labelling of catalytic AChE
using Ph-F and of its inability to mark non-catalytic
AChE. Sample extracts showed Ph-F labelled 70–76 kDa
proteins, whose intensity was fainter in HNSCC than
ANCT pieces (Fig. 5b) despite the similar labelling of
the 43-kDa β-actin band (Fig. 5c). The fact that the 60-
kDa protein failed in being marked by Ph-F supported
its assignment to catalytically inactive AChE.
Discussion
The results reported here demonstrated that human
upper airway truck epithelium possesses the capacity to
express a wide range of ACh-related proteins, such asAChE, BChE, nAChR, mAChR, and possibly ChAT.
These and previous observations [4] lent strong support
to the presence in airway epithelium (and possibly in
other epithelia) of a physiologically active non-neuronal
cholinergic system. This system is expected to be crucial
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ation of cholinergic inputs and down-stream events, in-
cluding cell growth and proliferation. In spite of the
abundant information on cancer-associated changes in
ChE activity, assembly of ChE subunits, and processing
of their linked oligoglycans in human breast, lymph
node, gut, lung, prostate and kidney [8, 19, 37], conclu-
sive proofs of a causal relationship of tumour aggressive-
ness with ChE changes are still lacking. Nevertheless,
several observations have lent weight to a possible role
of ChEs in tumorogenesis and tumour biology. These in-
clude: 1) the relationship of human astrocytoma aggres-
siveness and altered patterns of splice-derived AChE
variants [34]; 2) the increased labelling of cytoplasm-
residing AChE in ovarian cancer [38]; 3) the shorter
DFS and OS rates of patients carrying low AChE
activity-exhibiting hepatocarcinoma [23]; and 4) the low
ChE activity assayed in specimens of advanced prostate
cancer [39].
The significant and comparable levels of AChE and
BChE activities in ANCT (Table 1) demonstrated that
upper respiratory tract was able to regulate the available
ACh and, therefore, cholinergic signalling. Moreover, the
drop of AChE and BChE activities in head and neck can-
cers and the differences between ANCT and HNSCC
pieces in AChE, BChE, nAChR and mAChR mRNA
levels lent strong support to the notion that a non-
neuronal cholinergic system may be involved in head
and neck malignancy. The heretofore unnoticed obser-
vation that patients carrying HNSCC with AChE activity
below the cut-off value have a poorer survival rate
(Fig. 1) reminds very much the case of hepatocellular
carcinoma patients, for which a low level of AChE activ-
ity was found to be correlated with an increased risk of
post-operative recurrence [23]. These results strength-
ened the idea of a relationship between a low ACh-
hydrolyzing activity and tumour growth in both head
and neck carcinoma, and liver carcinoma at least. The
potent anti-tumour action that an AChE-loaded adeno-
viral vector exerts on gastric cancer cells [40] lends sup-
port to the tumour growth-promoting facet of ACh.
On the other hand, the well-known capacity of ACh
for blocking NFκB production [41, 42] makes it possible
that the increased ACh level, arising from the decreased
AChE activity in HNSCC and hepatic carcinoma,
tightens the blockade of cytokines production, which
may provide a tentative explanation for the poor survival
prospects of the patients afflicted of HNSCC with low
AChE activity. In addition, microRNA regulation may
offer key answers to the varying levels of ChE activity in
cancerous tissues. The observed changes in the mRNA
levels of the tested cholinergic proteins (Figs. 2 and 3)
may reflect, in addition to transcriptional differences,
changes in micro-RNA regulation [43–45]. In thisregards, it is worth mentioning the reported tumour-
suppressor activity that synaptic AChE (targeted by
miRNA-212) plays in non-small cell lung cancer [46].
This anti-tumour action not only provides a clear proof
of the involvement of AChE in tumorigenesis, but it also
confirms the participation of miRNA in the control of
AChE activity levels (and ACh availability), which en-
courages researchers to work in the novel and promising
field of microRNA-AChE regulation.
In addition, the results of Table 1 suggest a probable
causal relationship between cancer-promoting habits
(smoking or alcohol intake) and bad tumour prognosis
features, such as a poor differentiation stage. The results
of Table 1 also make possible that the statistical changes
in AChE activity levels between ANCT and HNSCC
were related with advanced tumour stages. In conclu-
sion, our results support the notion that the lower the
AChE activity in HNSCC, the greater the chance of a
poor prognosis, possibly owing to cholinergic over-
activation arising from an increased level of ACh in the
neighbourhood of cancerous cells. The fact that the dif-
ferences in AChE activity levels between HNSCC pieces
failed in reaching statistical significance with respect to
well-accepted pathological features (Table 1) suggested
that the decrease of AChE activity may represent an
early step in malignant transformation. Nevertheless, the
possibility remains that the lower AChE activity in
HNSCC represents a specific feature of the cell type
from which the tumour emanates.
Contrary to AChE activity, BChE activity above the me-
dian value was found associated with bad OS and DFS
rates (Table 1, and Fig. 1b, d). This result was unexpected
considering the ACh-hydrolyzing capacity of both BChE
and AChE, the former working less efficiently. BChE has
attracted much attention due to its capacity to hydrolyze
cocaine (and other toxic esters) and its ability to scavenge
nerve agents and organophosphorous pesticides [47].
Apart from this scavenging action, there is evidence that
BChE intervenes in the regulation of intrinsic inflamma-
tion and activity of cholinoceptive glial cells, whose appro-
priate activation and maintenance seem to provide
profitable responses [48, 49]. In addition, the repeatedly
observed drop of plasma BChE activity in conditions of
acute surgical and clinical illness, which lead to the so-
called acute phase response [50] may explain the better
prospects of patients carrying HNSCC with BChE activity
below the cut-off value.
The longer survival of patients carrying HNSCC with
higher AChE and lower BChE (Fig. 1e-f ) agreed with the
findings of others for post-stroke patients [51], whose
survival pace was related with higher serum AChE activ-
ity and lower BChE activity, and differed from the pros-
pects of patients who underwent cardiovascular events,
whose survival was found associated with higher serum
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remains that the increased average value for BChE activ-
ity in HNSCC reflects compensatory mechanisms to
overcome temporal (or permanent) deficiency (or loss)
of AChE [53]. If this were the case, an inverse correl-
ation between the decrease of AChE activity in cancer-
ous samples and the increase in BChE activity in them
should be expected. In support of the above idea there is
the fact that HNSCC exhibits decreased levels of the
principal AChE-T and AChE-H mRNAs and increased
levels of the BChE mRNA (Fig. 2). However, the re-
sponse of cells to the AChE deficiency seems to be in-
complete as showed the decreased AChE and BChE
activities in HNSCC.
The presence in unaffected and malign respiratory
tract epithelia of principal amphiphilic AChE dimers
(G2
A), most likely consisting of GPI-linked AChE (Fig. 4),
agreed with the molecular profiles observed in studies of
unaffected and cancerous breast and other epithelial tis-
sues [8, 25, 54]. The predominance in epithelial tissues
and blood cells of GPI-linked G2
A AChE, which arises
from the AChE-H mRNA, reinforces the idea that the
AChE-H mRNA variant is the principal source (if not the
only one) of AChE activity in the airway epithelium and
other non-nervous tissues [55]. The presence in most
ANCT specimens of nerve-born PRiMA-linked AChE tet-
ramers (Fig. 4), their lack from glottis- and supraglottis
cancerous pieces, and the presence in them of PRiMA-
linked BChE tetramers agreed with previous histological
observations showing tumour-associated remodelling and
loss of nerve terminals along head and neck cancer devel-
opment and motor nerve invasion [56].
Interestingly, the AChE gene expression was found to
vary in HSNCC according to their differentiation grade
(Additional file 1: Figure S2A-B). So, whilst poorly differ-
entiated tumours were able to maintain or even increase
the levels of the three AChE mRNA types, all of them
were found decreased in well or moderately differenti-
ated tumours. The increased AChE mRNA level in poorly
differentiated HSNCC may reflect the cell attempts to in-
crease catalytic AChE as a means to attenuate cholinergic
over-activation. Unfortunately, the attempts seem to be un-
successful given the lower AChE activity in cancerous than
non-cancerous pieces (Table 1). In addition, the decreased
AChE-T mRNA level in glottis-located tumours and its in-
creased level in supraglottis tumours (Fig. 2) made unlikely
AChE-T mRNA as the leading transcript for AChE activity
in unaffected and cancerous pieces. Instead, the decreased
AChE-H mRNA levels in glottis and supraglottis tumours
strongly supported the proposal of AChE-H mRNA as the
principal source of the enzyme activity in non-neural per-
ipheral tissues [55]. Moreover, the opposite changes in
AChE-T mRNA levels of glottis and supraglottis tumours
suggest that the particular environment surroundingtumour cells may determine transcriptional and post-
transcriptional events and, in the case of HNSCC at least,
without affecting the AChE gene splicing pattern. Of note
is the paradox of an enhanced AChE-T mRNA level in
supraglottis tumours and a lower AChE activity in them
(Table 1). Post-translational events, including conversion
of catalytically incompetent into competent subunits,
oligomerization, and rapid secretion of AChE-T made
oligomers may explain the lack of correlation between the
discrepant levels of AChE-T mRNA and of AChE hydro-
lyzing activity.
As a whole, the results reported herein unambiguously
demonstrate that AChE gene is down-regulated in
HNSCC. In support of this statement are the decreased
levels for AChE-T, AChE-H and ACh-R mRNAs (Fig. 2A),
the weaker labelling of 70–76 kDa catalytic subunits in can-
cerous pieces, and the fainter signal for non-catalytic 60-
kDa subunits in tumours pieces in pairs of ANCT and
HNSCC samples (Fig. 5). As for BChE, the decreased en-
zyme activity (Table 1) in head and neck carcinomas
contrasted with the increased mRNA levels in them.
This paradox might arise among other causes from de-
creased translation efficiency, shorter half-life of BChE
protein in tumours, or faster release of secretion-
destined BChE tetramers.
The identification in ANCT of mRNAs for nAChR,
mAChR, and ChEs (Fig. 3), and their changing levels in
HNSCC indicate that human upper aero-digestive tract epi-
thelium can produce protein components of a non-
neuronal cholinergic system. The observation in ANCT
and HNSCC of mRNAs for α7, α5, α3, and α9 AChR sub-
units (Fig. 3) might lend support to the Hainaut's group
proposal, according to which homomeric α7 receptors me-
diate in proliferative effects and heteromeric α3(β2/β4)α5
receptors in negative inputs [57]. Of note is the widely ac-
cepted consideration of α7 receptor as a key mediator of
pathological effects in airways of tobacco components [58].
The association of α7 nAChR with breast cancer [59] and
the risen α7 mRNA levels in HNSCC support the possibil-
ity that α7 nAChR is a target for head and neck cancer.
The first hint supporting a causal relationship of cho-
linergic activation with tumour growth came from stud-
ies showing the presence of AChR in cervical cancer
[60], colon cancer [61], non-small cell lung cancer [62,
63] and small cell lung cancer SCLC [64, 65]. Another
line of evidence stems from studies showing that im-
paired cholinergic activity due to abnormal AChR func-
tioning stimulates tumour growth by promoting several
hallmarks of cancer cells [66, 67]. Interestingly, the dif-
ferences in airway epithelium between smokers and
non-smokers in nAChR [10] and ACh-hydrolyzing en-
zymes (Fig. 2B) gene expression firmly support the pos-
sibility that the tobacco components are responsible for
the changed expression. Thus, it is tempting to speculate
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may lead to changes in the expression level of the pro-
tein components that form a pro-tumorogenic choliner-
gic system in airway epithelium characterized by an
upregulated, pro-proliferative homomeric α7 nicotinic
receptors and a downregulation of “inhibitory” nAChR
and ACh-hydrolyzing enzymes. The feeding of the system
by endogenous ACh would explain the high risk of tumor-
ogenesis that former smoker show after smoking cessation
for long time. The combination of increased nicotine-
induced ACh synthesis and decreased degradation due to
down-expressed ChEs can result in an increase in available
ACh in the tumour and to proliferative stimuli to both
‘tumoral’ mAChR and nAChR.
Summarizing, the fact that HNSCC-expressing low AChE
activity exhibit a poor prognosis raises the possibility of
using this low activity as a reliable prognosis predictor. The
increased ACh level, owing to the loss of ACh-hydrolysing
activity may lead to over-activation of ACh receptors. So,
cholinergic signalling and down-stream events may be ex-
acerbated in HNSCC and by this means favour tumour
growth and/or promote a more aggressive tumor pheno-
type. This study lends strong support regarding the poten-
tial use of AChE as a predictor of clinical outcomes, which,
eventually, may lead to novel strategies in drug design.
Conclusion
This study compared ACh-hydrolyzing activity and ex-
pression of ACh-related proteins in human upper airway
truck epithelium, and found that HNSCC-expressing
low AChE activity exhibit a poor prognosis and shorter
overall survival. Exacerbated cholinergic signalling and
down-stream events may favour tumour growth and/or
promote a more aggressive tumor phenotype. This study
lends strong support regarding the potential use of
AChE as a predictor of clinical outcomes, which, eventu-
ally, may lead to novel strategies in drug design.Additional file
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